secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-085942
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 5.02, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio closes acquisition of Spectrum Pharmaceuticals; expects accretion in 2024
--------------------------------------------------------------------------------

- Acquisition of Spectrum closed July 31, 2023; each Spectrum share converted into 0.1783 Assertio shares plus one CVR worth up to $0.20.
- Jeffrey Vacirca, MD, FACP, appointed to Assertio's board as independent director effective at closing.
- Transaction expected to be significantly accretive to Assertio's adjusted EPS and operating cash flow in 2024.
- Stockholders of both companies approved the deal; updated guidance to be provided on August 3 Q2 earnings call.
- Deal combines Assertio's digital sales with Spectrum's ROLVEDON commercial team to enhance market access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000110465923085942/0001104659-23-085942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000110465923085942/tm2322207d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer